The relevance of the immune system in controlling melanoma is generally accepted, and since the introduction of CTLA-4 single blockage (ipilimumab) in 2011, clinical application of ICIs for melanoma treatment has shown for the first time in history the impressive therapeutic potential of drugs that regulate immunosurveillance (1, 3). Here, CTLA4 is linked to melanoma.